Gasper Mason C, Ott Brian R, Lapane Kate L
Department of Clinical Neurosciences, Brown University, Providence, Rhode Island, USA.
Am J Geriatr Pharmacother. 2005 Mar;3(1):1-7. doi: 10.1016/j.amjopharm.2005.02.001.
Since cholinesterase inhibitors (CEIs) were approved for use in mild to moderate Alzheimer's disease, the therapeutic efficacy of this class of medications has largely centered on demonstration of short-term improvement in cognition and global function. Later evidence suggested that the beneficial effects of CEIs might be sustainable for at least 3 years and that CEIs may have a disease-modifying effect on Alzheimer's disease. These broad-ranging, long-term effects may explain the recent finding that the use of a CEI among nursing home residents with dementia was associated with lower mortality.
The goal of this study was to investigate whether donepezil treatment is associated with reduced mortality in nursing home residents who have dementia.
We performed a retrospective matched cohort study using the Systematic Assessment of Geriatric Drug Use via Epidemiology database, which contains data collected with the Minimum Data Set on a cross section of 915,469 nursing home residents aged > 65 years between 1998 and 2000 in 6 US states. We identified users of donepezil (5 and 10 mg) and an equal number of matched nonusers in the same facility, date of donepezil use, level of cognitive function, and dementia diagnosis. Comparisons of the 2 groups were made for sociodemographic variables, dementia severity, number of medications, and major comorbid illnesses (heart disease, cancer, diabetes mellitus, chronic obstructive pulmonary disease, and malnutrition), as well as survival over the 2-year study period.
A total of 5423 users and 5423 nonusers of donepezil were identified. Based on Cox proportional hazards models, donepezil users showed a lower mortality rate than nonusers. The hazard rate ratio was 0.89 (95% CI, 0.83-0.95). After adjusting for the confounding variables, sociodemographic factors, other psychotropic drugs, and comorbid conditions, this survival advantage remained (hazard rate ratio, 0.90; 95% CI, 0.84-0.96).
A relationship was observed between treatment of nursing home residents with donepezil and lower mortality. If the relationship was due to a direct effect of donepezil use, then this observation has implications for the socioeconomic impact of CEI therapy in those with advanced dementia in the nursing home. These implications deserve future investigation.
自从胆碱酯酶抑制剂(CEIs)被批准用于治疗轻至中度阿尔茨海默病以来,这类药物的治疗效果主要集中在短期内认知和整体功能的改善上。后来的证据表明,CEIs的有益效果可能至少可持续3年,并且CEIs可能对阿尔茨海默病具有疾病修饰作用。这些广泛的长期影响可能解释了最近的一项发现,即在患有痴呆症的养老院居民中使用CEI与较低的死亡率相关。
本研究的目的是调查多奈哌齐治疗是否与患有痴呆症的养老院居民死亡率降低相关。
我们使用通过流行病学进行老年药物使用系统评估数据库进行了一项回顾性匹配队列研究,该数据库包含1998年至2000年期间美国6个州915469名年龄>65岁的养老院居民横断面的最小数据集收集的数据。我们在同一机构、多奈哌齐使用日期、认知功能水平和痴呆症诊断中确定了多奈哌齐(5毫克和10毫克)使用者和数量相等的匹配非使用者。对两组进行社会人口统计学变量、痴呆症严重程度、药物数量和主要合并症(心脏病、癌症、糖尿病、慢性阻塞性肺疾病和营养不良)以及2年研究期间的生存率比较。
共确定了5423名多奈哌齐使用者和5423名非使用者。基于Cox比例风险模型,多奈哌齐使用者的死亡率低于非使用者。风险率比为0.89(95%CI,0.83-0.95)。在调整混杂变量、社会人口统计学因素、其他精神药物和合并症后,这种生存优势仍然存在(风险率比,0.90;95%CI,0.84-0.96)。
观察到在养老院居民中使用多奈哌齐与较低的死亡率之间存在关联。如果这种关联是由于使用多奈哌齐的直接作用,那么这一观察结果对养老院中晚期痴呆症患者CEI治疗的社会经济影响具有启示意义。这些启示值得未来进行研究。